课题基金 / 基金详情

Strategy for Therapy of the Pseudoachondroplasia (PSACH) Phenotype: Understanding

Strategy for Therapy of the Pseudoachondroplasia (PSACH) Phenotype: Understanding
假性软骨发育不全 (PSACH) 表型的治疗策略:了解
批准号:
7027908
负责人:
JACQUELINE T HECHT
金额:
$18.82万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-25 至 2007-08-31

项目摘要

项目成果

JACQUELINE T HECHT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mutations in cartilage oligomeric matrix protein (COMP) cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED/EDM1) both of which are associated with chronic joint abnormalities. The focus of this research is to determine whether the cellular pathology caused by the dominant negative effects of mutations in cartilage oligomeric matrix protein (COMP) can be reversed. In our previous work, we have demonstrated that mutations in COMP impede calcium-binding which is required for protein folding. Improperly folded mutant COMP is retained in enlarged rERcisternae along with type IX collagen, matrillin-3 and numerous chaperone proteins. This retention has the downstream effect of causing an extracellular matrix that is deficient in these proteins, a grossly disorganized matrix and eventual chondrocyte death. In contrast COMP null mice are normal suggesting that COMP is not necessary for cartilage and bone development and homeostasis. We hypothesize that removal of mutant COMP will reverse and established PSACH cellular phenotype and restore chondrocyte function and normal matrix formation. To test this hypothesis, we will now define the temporal pathway of the pathology and its resolution by using an inducible promoter system. We have successfully over-expressed mutant COMP in a 3-D culture system to recapitulate the disease pathology in normal human chondrocytes. The tetracycline (TET) inducible promoter and DMA expressing the TET-activated transcription factor (rtTA) will be used to both induce the cellular phenotype and to repress the production of mutant COMP. These experiments will be conducted in human primary growth plate chondrocytes and in transgenic mice. These studies will allow us to determine the timing of phenotype development and whether the phenotype is reversible, which is an important step towards toward developing a treatment intervention for these debilitating orthopedic dwarfing conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leveraging novel methods to improve nonsyndromic cleft lip/palate gene discovery
Leveraging novel methods to improve nonsyndromic cleft lip/palate gene discovery
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic M
Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic M
国内基金
海外基金
HIF-1α调控软骨细胞衰老在骨关节炎进展中的作用及机制研究
  • 批准号:
    82371603
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈晓
  • 依托单位: